David Mathai, MD completed his medical training and Psychiatry Residency at Baylor College of Medicine in Houston, Texas before joining the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine.
He is interested in interdisciplinary approaches to psychopharmacology research and has studied behavioral models of addiction and cognitive impairment, neuropsychiatric effects of cannabis, and antidepressant properties of ketamine. His current postdoctoral work focuses on applications of psychedelic medicine within phenomenologically- and psychologically-oriented frameworks. He is fascinated by psychedelics as a tool for therapeutic change and recognizes the need for thoughtful and nuanced treatment paradigms that account for the complexity of human experience. He is also interested in contextual factors shaping drug response, the judicious use of medication, and serving as a liaison between existing clinical and academic communities.
Clinically, Dr. Mathai works as a psychiatrist for Addiction Treatment Services (ATS) at Johns Hopkins Bayview Medical Center and as a guide for psilocybin sessions. He has received recognition for medical student education and psychotherapy along with awards for his scholarly work.